These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 37358705

  • 1. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
    Sussell JA, Press DJ, Hansen SA, Kim E, Du Toit Y, Fung A.
    Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705
    [Abstract] [Full Text] [Related]

  • 2. Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.
    Williamson M, Press DJ, Hansen SA, Tomar A, Jhuti GS, Revil C, Gururaj K.
    Breast Cancer; 2024 Jan; 31(1):84-95. PubMed ID: 37907759
    [Abstract] [Full Text] [Related]

  • 3. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, Darcourt JG, Meisel JL, Li X, Zhao J, Kuhn JG, Rosato RR, Qian W, Belcheva A, Schwartz MR, Kaklamani VG, Chang JC.
    Breast Cancer Res; 2019 Sep 02; 21(1):100. PubMed ID: 31477168
    [Abstract] [Full Text] [Related]

  • 4. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D.
    Lancet Oncol; 2018 Jan 02; 19(1):115-126. PubMed ID: 29175149
    [Abstract] [Full Text] [Related]

  • 5. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
    Hamilton EP, Kaklamani V, Falkson C, Vidal GA, Ward PJ, Patre M, Chui SY, Rotmensch J, Gupta K, Molinero L, Li Y, Emens LA.
    Clin Breast Cancer; 2021 Dec 02; 21(6):539-551. PubMed ID: 34154926
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States.
    Sussell J, Singh Jhuti G, Antao V, Herrera-Restrepo O, Wehler E, Bilir SP.
    Am J Clin Oncol; 2021 Jul 01; 44(7):340-349. PubMed ID: 34151896
    [Abstract] [Full Text] [Related]

  • 7. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
    Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L.
    JAMA Netw Open; 2020 Nov 02; 3(11):e2027074. PubMed ID: 33226431
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
    Lu D, Li C, Riggs M, Polhamus D, French J, Agarwal P, Chen SC, Vadhavkar S, Patre M, Strasak A, Quartino A, Jin JY, Girish S.
    Cancer Chemother Pharmacol; 2019 Jul 02; 84(1):175-185. PubMed ID: 31102024
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
    Takano T, Masuda N, Ito M, Inoue K, Tanabe Y, Kawaguchi K, Yasojima H, Bando H, Nakamura R, Yamanaka T, Ishida K, Aruga T, Yanagita Y, Tokunaga E, Aogi K, Ohno S, Kasai H, Kataoka TR, Morita S, Toi M.
    Breast Cancer Res Treat; 2024 Aug 02; 207(1):33-48. PubMed ID: 38767786
    [Abstract] [Full Text] [Related]

  • 10. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    Al Rabadi LS, Cook MM, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI.
    BMC Cancer; 2021 Oct 27; 21(1):1150. PubMed ID: 34706686
    [Abstract] [Full Text] [Related]

  • 11. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, Chang JC, Patre M, Strasak A, de Haas SL, Xu J, Garcia-Saenz JA.
    Ann Oncol; 2016 Jul 27; 27(7):1249-56. PubMed ID: 27052654
    [Abstract] [Full Text] [Related]

  • 12. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
    Conte B, Fabi A, Poggio F, Blondeaux E, Dellepiane C, D'Alonzo A, Buono G, Arpino G, Magri V, Naso G, Presti D, Mura S, Fontana A, Cognetti F, Molinelli C, Pastorino S, Bighin C, Miglietta L, Boccardo F, Lambertini M, Del Mastro L, Gruppo Italiano Mammella (GIM) study group.
    Clin Breast Cancer; 2020 Apr 27; 20(2):e181-e187. PubMed ID: 31735691
    [Abstract] [Full Text] [Related]

  • 13. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
    Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N.
    J Clin Oncol; 2022 Feb 10; 40(5):438-448. PubMed ID: 34890214
    [Abstract] [Full Text] [Related]

  • 14. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).
    Antolín Novoa S, Escrivá-de-Romaní S, Tolosa Ortega P, Oliva Fernández L, López López R, López González A, de la Morena Barrio P, Echavarria Díaz-Guardamino I, Alés Martinez JE, Garate Z, González-Cortijo L.
    Cancer Treat Res Commun; 2023 Feb 10; 37():100772. PubMed ID: 37995519
    [Abstract] [Full Text] [Related]

  • 15. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
    de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, Prat A, Lopez-Valverde V, Boulet T, Hurvitz SA.
    Breast Cancer Res; 2023 Jan 11; 25(1):2. PubMed ID: 36631725
    [Abstract] [Full Text] [Related]

  • 16. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE, KATHERINE Investigators.
    N Engl J Med; 2019 Feb 14; 380(7):617-628. PubMed ID: 30516102
    [Abstract] [Full Text] [Related]

  • 17. Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model.
    Hendrix N, Oestreicher N, Lalla D, Dolan CM, Fisher KA, Veenstra DL, Moy B.
    Clin Breast Cancer; 2022 Dec 14; 22(8):781-791. PubMed ID: 36220724
    [Abstract] [Full Text] [Related]

  • 18. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
    Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M.
    Breast Cancer Res Treat; 2020 Feb 14; 180(1):135-146. PubMed ID: 31953696
    [Abstract] [Full Text] [Related]

  • 19. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
    Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchiò C, Krasniqi E, Barba M, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Barchiesi G, Mazzotta M, Marinelli D, Tomao S, Marchetti P, Valerio MR, Mirabelli R, Russo A, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Giotta F, Garufi C, Cazzaniga M, Del Medico P, Roselli M, Sanguineti G, Sperduti I, Sapino A, De Maria R, Leonetti C, Di Leo A, Ciliberto G, Falcioni R, Vici P.
    J Exp Clin Cancer Res; 2020 Dec 10; 39(1):279. PubMed ID: 33302999
    [Abstract] [Full Text] [Related]

  • 20. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
    O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH.
    Future Oncol; 2021 Dec 10; 17(34):4665-4676. PubMed ID: 34636255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.